Literature DB >> 3123586

Molecular cloning of a human apoC-III variant: Thr 74----Ala 74 mutation prevents O-glycosylation.

H Maeda1, R K Hashimoto, T Ogura, S Hiraga, H Uzawa.   

Abstract

Apolipoprotein C-III (apoC-III) is a major protein of very low density lipoprotein (VLDL). The apoC-III polypeptide contains a carbohydrate chain containing galactosamine, galactose, and sialic acid attached in O-linkage to a threonine residue at position 74. We have cloned the apoC-III gene from a subject whose serum contained unusually high amounts of apoC-III lacking the carbohydrate moiety (C-III-0). DNA sequence analysis of the cloned gene revealed a single nucleotide substitution (A----G) that encodes an alanine at position 74 instead of the normal threonine. As a result of this amino acid replacement, the mutant apoC-III polypeptide is not glycosylated. The mutation in the apoC-III gene creates a novel AluI site that permits diagnosis of the change by Southern blotting of genomic DNA.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3123586

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  10 in total

1.  Quantitative analysis of intact apolipoproteins in human HDL by top-down differential mass spectrometry.

Authors:  Matthew T Mazur; Helene L Cardasis; Daniel S Spellman; Andy Liaw; Nathan A Yates; Ronald C Hendrickson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-13       Impact factor: 11.205

2.  Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man.

Authors:  Adriaan G Holleboom; Helen Karlsson; Ruei-Shiuan Lin; Thomas M Beres; Jeroen A Sierts; Daniel S Herman; Erik S G Stroes; Johannes M Aerts; John J P Kastelein; Mohammad M Motazacker; Geesje M Dallinga-Thie; Johannes H M Levels; Aeilko H Zwinderman; Jonathan G Seidman; Christine E Seidman; Stefan Ljunggren; Dirk J Lefeber; Eva Morava; Ron A Wevers; Timothy A Fritz; Lawrence A Tabak; Mats Lindahl; G Kees Hovingh; Jan Albert Kuivenhoven
Journal:  Cell Metab       Date:  2011-12-07       Impact factor: 27.287

3.  Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia.

Authors:  A von Eckardstein; H Holz; M Sandkamp; W Weng; H Funke; G Assmann
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

4.  Affinity enrichment and characterization of mucin core-1 type glycopeptides from bovine serum.

Authors:  Zsuzsanna Darula; Katalin F Medzihradszky
Journal:  Mol Cell Proteomics       Date:  2009-08-12       Impact factor: 5.911

5.  Mass spectrometric identification of aberrantly glycosylated human apolipoprotein C-III peptides in urine from Schistosoma mansoni-infected individuals.

Authors:  Crina I A Balog; Oleg A Mayboroda; Manfred Wuhrer; Cornelis H Hokke; André M Deelder; Paul J Hensbergen
Journal:  Mol Cell Proteomics       Date:  2010-01-13       Impact factor: 5.911

6.  The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation.

Authors:  Meenakshi Sundaram; Kaitlin R Curtis; Mohsen Amir Alipour; Nicholas D LeBlond; Kaitlyn D Margison; Rebecca A Yaworski; Robin J Parks; Adam D McIntyre; Robert A Hegele; Morgan D Fullerton; Zemin Yao
Journal:  J Lipid Res       Date:  2017-09-08       Impact factor: 5.922

7.  Reduced apolipoprotein glycosylation in patients with the metabolic syndrome.

Authors:  Olga V Savinova; Kristi Fillaus; Linhong Jing; William S Harris; Gregory C Shearer
Journal:  PLoS One       Date:  2014-08-12       Impact factor: 3.240

Review 8.  The Tn antigen-structural simplicity and biological complexity.

Authors:  Tongzhong Ju; Vivianne I Otto; Richard D Cummings
Journal:  Angew Chem Int Ed Engl       Date:  2011-01-21       Impact factor: 15.336

9.  Targeting the glycoproteome.

Authors:  Jonas Nilsson; Adnan Halim; Ammi Grahn; Göran Larson
Journal:  Glycoconj J       Date:  2012-08-11       Impact factor: 2.916

10.  A rare functional cardioprotective APOC3 variant has risen in frequency in distinct population isolates.

Authors:  Ioanna Tachmazidou; George Dedoussis; Lorraine Southam; Aliki-Eleni Farmaki; Graham R S Ritchie; Dionysia K Xifara; Angela Matchan; Konstantinos Hatzikotoulas; Nigel W Rayner; Yuan Chen; Toni I Pollin; Jeffrey R O'Connell; Laura M Yerges-Armstrong; Chrysoula Kiagiadaki; Kalliope Panoutsopoulou; Jeremy Schwartzentruber; Loukas Moutsianas; Emmanouil Tsafantakis; Chris Tyler-Smith; Gil McVean; Yali Xue; Eleftheria Zeggini
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.